Clinical trials
Cystocele trials with no applicable phase
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
38 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 1 |
| 2004 | 1 |
| 2005 | 3 |
| 2006 | 3 |
| 2007 | 1 |
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 1 |
| 2014 | 3 |
| 2015 | 1 |
| 2016 | 5 |
| 2017 | 3 |
| 2018 | 2 |
| 2019 | 1 |
| 2021 | 3 |
| 2022 | 2 |
| 2023 | 2 |
| 2024 | 1 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 20 |
| Unknown status | 9 |
| Active, not recruiting | 3 |
| Recruiting | 3 |
| Terminated | 2 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Ain Shams Maternity Hospital | 2 |
| Centre Hospitalier Universitaire de Nīmes | 2 |
| University Hospital, Lille | 2 |
| Al-Mustafa University College | 1 |
| Atlantic Health System | 1 |
| Atrium Medical Center | 1 |
| Cassandra Kisby | 1 |
| Charles University, Czech Republic | 1 |
| Francisco Carmona | 1 |
| Geisinger Clinic | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Cystocele | 38 |
| Pelvic Organ Prolapse | 20 |
| Uterine Prolapse | 16 |
| Rectocele | 12 |
| Prolapse | 8 |
| Hernia | 6 |
| Urinary Incontinence | 3 |
| Urinary Incontinence, Stress | 3 |
| Pelvic Floor Disorders | 2 |
| Cystitis | 1 |
Trials
Showing 26 to 38 of 38. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.